Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6119517 | 0.84 | RAB9A (0.37) | CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL2436747 | 0.83 | AR (0.45) | CYP3A4KCNH2CYP2C8 | |
| SCHEMBL19242439 | 0.79 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19KCNH2CYP2C8 | |
| SCHEMBL4304092 | 0.78 | CYP3A4 (0.58) | CYP3A4CYP2C9CYP2C19KCNH2CYP2C8 | |
| SCHEMBL18038612 | 0.77 | KCNH2 (0.43) | CYP3A4KCNH2CYP2C8 | |
| SCHEMBL1919191 | 0.76 | L3MBTL1 (0.53) | CYP3A4KCNH2CYP2C8 | |
| SCHEMBL5518511 | 0.75 | CYP2C9 (0.53) | CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL4314359 | 0.75 | CYP3A4 (0.55) | CYP3A4CYP2C9CYP2C19KCNH2CYP2C8 | |
| SCHEMBL20923772 | 0.75 | CYP3A4 (0.55) | CYP3A4CYP2C9CYP2C19KCNH2CYP2C8 | |
| SCHEMBL1918634 | 0.75 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19KCNH2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2744332-A1 | BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | Glaxo Group Limited (GB) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013028371-A1 | BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS | GLAXO GROUP LIMITED (GB) | 2013-02-28 | — | — | WO | disclosed |
| WO-2012067663-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |